For instance, the administration of 3-Deazaneplanocin A (DZNep) has been shown to effectively inhibit the specific binding of EZH2 to the proximal promoter of PTEN, thereby reducing the transcription level of PTEN mRNA and improving the pathological damage of CKD (15). This evidence concerns the gene PTEN and chronic kidney disease.